Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 101–200 of 892
Acute heart failure in non-cardiac surgery
Gualandro, D. M., Masip, J., Halvorsen, S., Price, S., Rosselló, X., Chioncel, O. D., Peacock, W. F., Miró, Ò., de Oliveira, M. T., Mebazaa, A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf559 · Cited by 17
“89 Additional patient-level meta-analysis of randomized trials suggested that the use of MRAs in HFmrEF and HFpEF reduces the risk of re-hospitalizations.”
Self-citationRisk of Hyperkalemia With Empagliflozin, Finerenone, or Both
Agarwal, R., Green, J. B., Heerspink, H. J. L., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., Rossing, P. R., Vaduganathan, M., Solis‐Herrera, C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.049 · Cited by 20
Self-citationHeart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 17
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction
Bonfioli, G. B., Pagnesi, M., Calò, L., & Metra, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae095 · Cited by 20
“10 Nowadays, apart from SGLT2i and diuretic therapy when needed, the management of HFpEF is based on the different aetiologies and comorbidities (both cardiovascular and non-cardiovascular).”
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction
Ostrominski, J. W., Filippatos, G., Claggett, B. L., Miao, Z. M., Desai, A. S., Jhund, P. S., Henderson, A. D., Scheerer, M. F., Rohwedder, K., Amarante, F., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.041 · Cited by 17
Self-citationHong, D., Song, S.-H., Shin, H., Bak, M., Kim, J., Kim, D., Kim, J. Y., Yang, J. H., Park, S.-J., Choi, J.-O., et al. (2025) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztaf080 · Cited by 14
“17 These advancements emphasize the need for accurate and timely diagnosis to enable early initiation of evidence-based therapies.”
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 17
Self-citationCunningham, J. W., Chatur, S., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., Esperón, G. L., Lam, C. S. P., Sato, N., Senni, M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0016 · Cited by 16
Self-citationHelmeczi, W., & Hundemer, G. L. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001067 · Cited by 18
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., Klingenberg, R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf012 · Cited by 18
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Lam, C. S. P., Mueller, K., Scheerer, M. F., Viswanathan, P., Senni, M., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3661 · Cited by 18
Self-citationGreene, S. J., Butler, J., & Fonarow, G. C. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0038 · Cited by 13
Wu, J., Tseng, K., & Lin, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.043373 · Cited by 15
Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications
Ye, M., Feng, S., Xu, Z., He, W., Liu, C., & Zhu, W. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156460 · Cited by 17
Tanaka, A., Vaduganathan, M., Imai, T., Okada, Y., Sonoda, S., Torimoto, K., Suwa, S., Teragawa, H., Miyazono, M., Fukuda, M., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03014-x · Cited by 16
“Similarly, in participants with heart failure in the FINEARTS-HF [26], early modest reductions in systolic blood pressure [− 3.4 mm Hg (95%CI − 2.6 to − 4.2)] with finerenone did not account for the long-term cardiovascular benefits of the therapy.”
InfluentialSelf-citationKidney Disease and Heart Failure: Recent Advances and Current Challenges
Lam, C. S. P., Bozkurt, B., Cherney, D. Z. I., Ezekowitz, J. A., Jardine, M., Khan, S. S., Madero, M., Sarnak, M. J., ter Maaten, J. M., Cheung, M., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.102943 · Cited by 21
“86 Among the study population, the median (interquartile range) baseline eGFR was 61 (47–77) ml/min per 1.73 m 2 , and 2785 people (48”
InfluentialSelf-citationMendieta, G., Ridker, P. M., Borlaug, B. A., Ducharme, A., Lam, C. S. P., Voors, A. A., Auerbach, P., Čikeš, M., Fudim, M., Hvelplund, A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag153 · Cited by 20
“45,49,50 Of note, dapagliflozin did not improve health status in HFpEF in the DETERMINE trial, 51 whereas it resulted in a small improvement in the DELIVER trial, 50 with a larger effect size in those with HFpEF and higher body mass.”
InfluentialSelf-citationYoshida, Y., & Shibata, H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01970-7 · Cited by 15
“Furthermore, Solomon et al. [42] found that fi nerenone reduced worsening heart failure and cardiovascular mortality in patients with mild heart failure with or without diabetes.”
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure
Pitt, B., & Vaidya, A. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.021 · Cited by 16
Self-citationSTOUGAARD, E. B., Andersen, M. R., Bagger, J. I., Søndergaard, E., Østergaard, J. A., Curovic, V. R., Persson, F., Almdal, T., Mathiesen, A. S., Andries, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16606 · Cited by 14
“11,49,50 Results from the FINEARTS-HF trial were presented at this year's European Society of Cardiology (ESC) Congress 51 and demonstrated that finerenone significantly reduced the rate of a composite of total worsening HF events and death from cardiovascular causes compared with placebo.”
Current Treatment of Heart Failure with Preserved Ejection Fraction
Riccardi, M., D’Elia, E., Lombardi, C., Savarese, G., Gori, M., Oliva, F. G., Volterrani, M., Senni, M., Metra, M., & Inciardi, R. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155406 · Cited by 13
“The study showed a reduction in a composite of total worsening HF events and death from CV causes in patients treated with finerenone compared to placebo (risk ratio 0.84; 95% confidence interval, 0.74–0.95; p = 0.007), driven by a significant reduction in HF events [38,39].”
InfluentialSelf-citationSGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Liakos, A., Karagiannis, T., Avgerinos, I., & Bekiari, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-025-01616-z · Cited by 21
“…have thus far been demonstrated only with specific agents such as subcutaneous semaglutide [25 ], the first in class dual glucose-dependent insulinotro - pic polypeptide/GLP-1 receptor agonist tirzepatide [26], as well as the nonsteroidal mineralocorticoid receptor antagonist finerenone [ 27 ].”
Shahid, I., Khan, M. S., Butler, J., Fonarow, G. C., & Greene, S. J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10481-7 · Cited by 16
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Desai, A. S., Jhund, P. S., Vaduganathan, M., Claggett, B. L., Cunningham, J. W., Pabón, M. A., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0860 · Cited by 12
Self-citationThe role of finerenone in heart failure
Ismahel, H., & Docherty, K. F. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.05.002 · Cited by 13
Ferreira, J. P., Marques, P. S., Leite, A. R., Neves, J. S., Zannad, F. M., & Pitt, B. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.002 · Cited by 15
Self-citationTaub, P. R., Greene, S. J., & Fudim, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10520-3 · Cited by 15
Ebong, I., Gill, A., Appiah, D., & Mauricio, R. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10528-9 · Cited by 17
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Wijkman, M. O., Lee, J. Y., Hof, J. V., Shah, A. M., Biering‐Sørensen, T., Solomon, S. D., Brown, J. M., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0068 · Cited by 15
Self-citationKittleson, M. D., Panjrath, G. S., Bates, K., Breathett, K. K., Dixon, D. L., Januzzi, J. L., & Mohammed, S. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.018 · Cited by 25
Chen, X., Huang, M., Chen, Y., Xu, H., & Wu, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10455-1 · Cited by 13
Ciutac, A. M., Pana, T. A., Dawson, D. K., & Myint, P. K. (2025) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241309673 · Cited by 13
“Hypertensive pregnancy disorders are associated with a two-fold increased risk of incident HF.”
InfluentialFuerlinger, A., Stockner, A., Sedej, S., & Abdellatif, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02566-8 · Cited by 12
Finerenone Across the Spectrum of Kidney Risk in Heart Failure
Ostrominski, J. W., Causland, F. R. M., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F. M., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.006 · Cited by 18
Self-citationVranken, N. P. A., Li, X., Bouman, H. J., Mourmans, S. G. J., Achten, A., Aizpurua, A. B., Rocca, H. B., Knackstedt, C., van Empel, V. P. M., & Weerts, J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02708-6 · Cited by 15
“A recent trial with a non-steroidal MRA in HFpEF, finere-none, demonstrated improved outcomes and reduced albuminuria, but it has not yet been proven that reducing albuminuria was a strong mediator to improve outcomes [40, 41].”
Advancing antihypertensive drug development
Pu, F., Liu, Y., Ahmed, F. Z., Wang, X., Green, D., & Zhang, H. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70063 · Cited by 18
“The FINEARTS-HF trial further expanded the cardioprotective potential of finerenone in heart failure with preserved ejection fraction (HFpEF), showing significant reductions in worsening heart failure events and cardiovascular death (Solomon et al., 2024).”
Bauersachs, J. K., Kato, E. T., & Rangaswami, J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15345 · Cited by 12
“71 In the prespeci fi ed FINE-HEART analysis, which pooled data from FIDELIO-DKD, FIGARO-DKD and FINEARTS-HF, the primary endpoint of CV death occurred in 4.4% of participants in the fi nerenone group and in 5.0% of participants in the placebo group (HR, 0.89; 95% CI, 0.78 – 1.01; P = 0.076) and this…”
InfluentialSelf-citationAllahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 23
“These findings suggest that combined use of finerenone and SGLT2is may offer additive CV protection in patients with HFmrEF and HFpEF [187].”
Gil, P., Gimeno-Orna, J. A., Padial, L. R., Muñiz, J., Barrios, V., Anguita, M. P., & Pérez, A. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02995-z · Cited by 16
“Beyond SGLT2i, the FINEARTS-HF trial demonstrated that finerenone significantly reduced HF hospitalizations and cardiovascular death in HFpEF [42] and recent pooled analyses from SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials further show that semaglutide reduces the risk of the composite…”
Lam, C. S. P., Bozkurt, B., Cherney, D. Z. I., Ezekowitz, J. A., Jardine, M., Khan, S. S., Madero, M., Sarnak, M. J., ter Maaten, J. M., Cheung, M., et al. (2026) · Kidney International · doi:10.1016/j.kint.2025.10.011 · Cited by 16
Self-citationParizad, R., Hatwal, J., Sadeghi, M. T., Brar, A. S., Desai, R., Batta, A., & Mohan, B. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s578698 · Cited by 14
“61,62 In obesity-related HFpEF, the STEP-HFpEF program demonstrated that semaglutide improved symptoms, physical function, exercise capacity, and reduced inflammation/weight, with pooled analyses showing lower risks of CV death or HF events.”
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 15
“…and LVEF ≥ 40% randomized to finerenone or placebo, finerenone was associated with a significant reduction in the primary composite of total worsening HF events and death from cardiovascular causes (rate ratio 0.84; 95% CI 0.74–0.95; P = 0.007), driven predominantly by a decrease in HF events 85 .”
InfluentialSotomayor-Julio, A. D., Seni-Molina, S., Gutiérrez‐Posso, J. M., Muñoz-Ordoñez, J. A., Azcárate-Rodríguez, V., León-Giraldo, H., Perna, E. R., Rossel, V., Quesada-Chaves, D., Speranza, M., et al. (2025) · Global Heart · doi:10.5334/gh.1418 · Cited by 15
Kondo, T., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., BRINKER, M. D., Lay‐Flurrie, J., Schloemer, P., Viswanathan, P., Amarante, F., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3669 · Cited by 11
Self-citationOzaki, Y., Uemura, Y., Kondo, T., Kazama, S., Yamaguchi, S., Okajima, T., Mitsuda, T., Ishikawa, S., Takemoto, K., Okumura, T., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0092 · Cited by 11
Sabina, M., Trube, J., Shah, S., Lurie, A., Grimm, M., & Bizanti, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216398 · Cited by 11
“The trial found that Finerenone significantly reduced heart failure events, primarily by decreasing recurrent hospitalizations or urgent visits, although it did not achieve a statistically significant reduction in cardiovascular mortality [31].”
BackgroundSelf-citationSex differences in diagnosis and treatment of heart failure: toward precision medicine
Lee, S. Y., & Park, S. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.338 · Cited by 10
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model
McDowell, K., Docherty, K. F., Campbell, R. T., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Lay‐Flurrie, J., Hofmeister, L. H., Scalise, A. V., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0025 · Cited by 11
Self-citationVenema, C. S., van Bergeijk, K. H., Krikken, J. A., van der Werf, H. W., van den Heuvel, A. F. M., Douglas, Y. L., Mordi, I. R., Girerd, N., Lang, C. C., Lam, C. S. P., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038786 · Cited by 9
Self-citationChimura, M., Yang, M., Henderson, A. D., Jhund, P. S., Docherty, K. F., Claggett, B. L., Desai, A. S., Filippatos, G., Gajos, G., Mueller, K., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3682 · Cited by 11
Self-citationFerreira, J. P., Vasques‐Nóvoa, F., Saraiva, F. A., Oliveira, A., Almeida, J., Batista, A. B., Barbosa, A., Ferreira, A. F., Costa, C., Santos‐Ferreira, D., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15294 · Cited by 9
“9,10 Despite the bene fi ts of SGLT2i and MRA to improve HF outcomes in HFmr/pEF, these treatments have not been tested together in a randomized manner, that is, MRA could be part of the background therapy in SGLT2i trials, and SGLT2i could be part of the background therapy in MRA trials.”
Self-citationChen, Y., Fang, Y.-W., Chen, M., Liou, H., & Tsai, M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf048 · Cited by 11
“…fraction, finerenone use resulted in a significantly lower rate of worsening heart failure events and cardiovascular deaths compared to placebo 28 The FINE-ONE trial will explore the efficacy and safety of finerenone in patients with type 1 diabetes and CKD 29 The CONFIDENCE study aims to…”
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Self-citationBlinded Withdrawal of Finerenone After Long-Term Treatment in the FINEARTS-HF Trial
Vaduganathan, M., Claggett, B. L., Udell, J. A., Desai, A. S., Jhund, P. S., Henderson, A. D., Lay‐Flurrie, J., Amarante, F., Glasauer, A., Lam, C. S. P., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.05.038 · Cited by 9
Self-citationChimura, M., Jhund, P. S., Henderson, A. D., Yang, M., Claggett, B. L., Desai, A. S., Rohwedder, K., Lage, A. Z., Scalise, A. V., Mueller, K., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.2551 · Cited by 10
Self-citationBorlaug, B. A., Zile, M. R., Kramer, C. M., Litwin, S. E., Ye, W., Ou, Y., Hurt, K. C., Murakami, M., & Packer, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf663 · Cited by 11
Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
Zhang, Y., Bao, Y.-C., Wang, L.-X., Zhao, H.-J., Sun, J., Sun, L., Duan, W., Du, M., Wang, L., An, Q.-Y., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1667236 · Cited by 15
“In September 2024, FINEARTS showed fi nerenone signi fi cantly reduced the composite of worsening HF events and cardiovascular (CV) death, providing robust evidence for its use in HFmrEF and HFpEF (3).”
InfluentialMyakala, K., Wang, X. X., Shults, N. V., Hughes, E. P., Ribeiro, P. D. C., Penjweini, R., Link, K. A., Barton, K., Krawczyk, E., Paredes, C. C., et al. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00136.2025 · Cited by 14
Salah, H. M., Ambrosy, A. P., Biegus, J., Bocchi, E. A., Butler, J., Chioncel, O. D., Cotter, G., Davison, B. A., Dzudié, A., Freund, Y., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.09.020 · Cited by 11
Self-citationChronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction
Packer, M., Testani, J. M., Butler, J., Zannad, F. M., Lam, C. S. P., Vaduganathan, M., Fang, J. C., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.086 · Cited by 15
Self-citationChioncel, O. D., Savarese, G., Laroche, C., Amir, O., Tokmakova, M. P., Cannata, A. N., Do, D. L., Kafafy, T. A., Krejčí, J., Moura, B., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70065 · Cited by 13
Self-citationKobayashi, M., Bozkurt, B., Myhre, P. L., López‐Azor, J. C., Guzik, M., Iwanek, G., Baudry, G., Marcos, M. C., Miró, Ò., Dauw, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70079 · Cited by 11
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction
Valente, V., Beer, B. N., & Savarese, G. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0111 · Cited by 10
“22,116) The forthcoming HF guidelines may likely incorporate corresponding treatment recommendations, although the review process by the European Medicines Agency is still ongoing.”
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 14
“Finerenone also reduced MACEs in people with HF and mildly reduced or preserved ejection fraction 144 .”
Soulié, M., Stéphan, Y., Durand, M., Lima‐Posada, I., Palacios, R., Nicol, L., López‐Andrés, N., Mulder, P. G. H., & Jaisser, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-74934-z · Cited by 11
“The FINEARTS-HF trial recently showed that, in patients with heart failure and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from CV causes than placebo 26 .”
Meyer, M., Núñez, J. E., Goyal, P., Silverman, D. N., van Berlo, J. H., & Maharaj, V. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.22 · Cited by 8
“The TOPCAT trial of spironolactone demonstrated a benefit in the participants from the Americas and finerenone confirmed this benefit [116,117] .”
Leptin and heart failure: the chicken or the egg?
Theodorakis, N., & Nikolaou, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10501-6 · Cited by 9
Finerenone and NYHA Functional Class in Heart Failure
Ostrominski, J. W., Vaduganathan, M., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F. M., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.007 · Cited by 10
Self-citationCurrent Practice of Guideline-Directed Medical Therapy After Acute Heart Failure Hospitalization
Kanaoka, K., Iwanaga, Y., Takegawa, K., Fujimoto, W., Nishioka, Y., Myojin, T., Okada, K., Noda, T., Imamura, T., & Miyamoto, Y. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.01.015 · Cited by 9
When a meta-analysis can be really useful?
Basile, C., Villaschi, A., & Maggioni, A. P. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133423 · Cited by 10
Mark, P. B., Sousa‐Amorim, E. D., Eriksson, A. L., Leonsson‐Zachrisson, M., Guzman, N. J., Miller, M. T., Jiang, Y., & Heerspink, H. J. L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf119 · Cited by 12
“The non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone and the glucagon-like peptide-1 receptor agonist semaglutide reduce the risk of kidney failure and cardiovascular disease in patients with CKD due to T2DM [2 –6 ].”
Romanò, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145090 · Cited by 9
“More recently the FINEARTS-HF trial demonstrated that the nonsteroidal MRA finerenone significantly reduced worsening HF or cardiovascular death in patients with HFmrEF/HFpEF, with the benefits fully attributable to reduced worsening HF [41].”
Finerenone According to Insulin Resistance in Heart Failure: Insights from the FINEARTS-HF Trial
Ostrominski, J. W., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F. M., Pitt, B., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70034 · Cited by 10
Self-citationLuedde, M., Agewall, S., Ambrosio, G., Bayés‐Genís, A., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70069 · Cited by 11
Self-citationHeart Failure Statistics 2025 Update: A Report From the Korean Society of Heart Failure
Lee, C. J., Lee, H., Ko, K., Kong, M. G., Kim, M. S., Bae, S., Ahn, Y., Chun, K., Choi, K.-U., Choi, J. Y., et al. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0001 · Cited by 9
“…metabolic and renal pathways, such as sodium-glucose cotransporter 2 inhibitors and finerenone, confer significant prognostic benefits in HF. 22,23) The integration of these agents as cornerstones of therapy likely reflects a paradigm shift, recognizing HF as a complex condition driven by…”
Masarone, D., Valente, F., Verrengia, M., Contaldi, C., Palma, V. D., Falco, L., Catapano, D., & di Lorenzo, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226867 · Cited by 7
“Additionally, the FINEARTS-HF study showed that finerenone considerably reduced the incidence of worsening heart failure events and cardiovascular-related deaths compared to placebo in patients with heart failure and mildly reduced or preserved ejection fraction [48].”
Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy
Schwarting, S. K., Bieber, T., Davies, D. R., Siepen, F. A. D., Schwarting, J., Grabmaier, U., Maßberg, S., Maurer, M. S., & Kääb, S. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011796 · Cited by 10
“57 European Society of Cardiology guidelines on HF recommend MRAs (Level IA) simultaneously with β -blockers and ACE inhibitors/ARBs in patients with HFrEF.”
Advances in the management of obesity and heart failure: latest evidence from clinical trials
Costa, T. A., & Harrington, J. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001214 · Cited by 7
“…mortality and worsening HF events (HR – – – there is an unmet need for further CVOTs specifically evaluating individuals with obesity and HFrEF, most data suggest that the use of semaglutide in patients with HFrEF and obesity may be both safe and effective at preventing cardiac events.”
Heart failure with preserved ejection fraction therapeutics: in search of the pillars
Rafei, A. E., Harrington, J., Tavares, C. A. M., Guimarães, P. O., Ambrosy, A. P., Bonaca, M. P., Sauer, A. J., Vardeny, O., & Canonico, M. E. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10524-z · Cited by 8
Self-citationOzaki, Y., Uemura, Y., Yamaguchi, S., Okajima, T., Mitsuda, T., Ishikawa, S., Takemoto, K., Murohara, T., & Watarai, M. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0056 · Cited by 9
Re-Evaluating Recurrent Events in Heart Failure Trials
Hazewinkel, A., Gregson, J., Pocock, S., McMurray, J. J. V., Solomon, S. D., Claggett, B. L., Packer, M., Anker, S. D., Ferreira, J. P., Docherty, K. F., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.543 · Cited by 8
Self-citationXu, Z., Li, X., Long, Y., He, A., Zou, Z., Wang, G., Xia, Y., & Luo, S. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167968 · Cited by 8
Pagnesi, M., Riccardi, M., Maisano, F., Grapsa, J., Barberis, V. I., Abdelhamid, M., Antohi, E., Arfsten, H., Karam, N., Muraru, D., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15405 · Cited by 10
Finerenone: Evidence for Benefit in Early Stages of Cardiovascular-Kidney-Metabolic Syndrome
Márquez, D. F., Ortíz, A., González‐Moreno, D., Ruilope, L. M., & Ruiz‐Hurtado, G. (2025) · Cardiorenal Medicine · doi:10.1159/000548494 · Cited by 8
“Encouragingly, recent data from the FINEARTS-HF trial [12], a large randomized study including 6,001 participants with a mean baseline UACR of 18 mg/g, revealed that in patients with no CKD, being 39% diabetic, finerenone reduced the risk of developing albuminuric CKD by 31% (A2 or A3 albuminuria)…”
Virani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 34
Self-citationRetractedHeart Failure With Mildly Reduced Ejection Fraction
Wu, L., Rizwan, A. M., Rodriguez, M., Hachem, K. E., Virk, H. U. H., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102476 · Cited by 13
Finerenone in Heart Failure—A Novel Therapeutic Approach
Holst-Hansen, A., Grimm, D. G., & Wehland, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413711 · Cited by 10
Mentz, R. J., Anker, S. D., Pitt, B., Rossing, P. R., Ruilope, L. M., Gebel, M., Kolkhof, P., Lawatscheck, R., Rohwedder, K., & Bakris, G. L. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3569 · Cited by 11
Self-citationLoop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction
Szabó‐Söderberg, B., Benson, L., Savarese, G., Hage, C., Guidetti, F., Thorvaldsen, T., Pitt, B., & Lund, L. H. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.04.029 · Cited by 7
Self-citationGlomerular pressure and tubular oxygen supply: a critical dual target for renal protection
Masuda, T., & Nagata, D. (2024) · Hypertension Research · doi:10.1038/s41440-024-01944-9 · Cited by 7
“The FINEARTS-HF randomized controlled trial of participants with HF and mildly reduced or preserved ejection fraction showed that fi nerenone signi fi cantly decreased the rate of a composite of total worsening HF events and death of cardiovascular causes compared to placebo [67].”
Zhang, Z., Wang, C., Liu, Q., Xiao, Y., Zhou, J., Wu, K., Huang, Y., Zhang, Z., Liu, S., & Lin, Q. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317721 · Cited by 8
Georgianos, P. I., Kourtidou, C., Kontogiorgos, I., Vaios, V., Leivaditis, K., Gossios, T. D., & Liakopoulos, V. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00723-2 · Cited by 6
“During a median follow-up period of 32 months, relative to placebo, finerenone lowered the occurrence of the primary efficacy outcome, defined as the composite of total (first and recurrent) worsening HF events or cardiovascular death by 16% (HR 0.84; 95% CI 0.74–0.95) [26].”
InfluentialCardiometabolic Phenotype in HFpEF: Insights from Murine Models
Ogurtsova, E., Arefieva, T. I., Filatova, A. Y., Radyukhina, N. V., & Ovchinnikov, A. G. (2025) · Biomedicines · doi:10.3390/biomedicines13030744 · Cited by 7
“To date, regarding the drugs that have been proven to be effective in HFrEF treatment, sodium–glucose transporter 2 inhibitors and mineralocorticoid receptor antagonists are the only ones that seem to improve the prognosis of patients with HFpEF by preventing HF exacerbations [8–10].”
Hyperkalemia risk of finerenone versus spironolactone in CKD patients with type 2 diabetes
Idowu, A. B., Lo, K. B., Adebolu, O., Hamilton, M., Abdelmaseeh, P., Navaneethan, S. D., & Rangaswami, J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf098 · Cited by 7
Ono, R., & Falcão, L. M. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2025.02.007 · Cited by 11
Calcagno, T., Issa, R., Massad, F. I., Kaelber, D. C., Martyn, T., & Agdamag, A. C. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.06.013 · Cited by 6
Brown, J. M., & Huck, D. M. (2025) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2025.102299 · Cited by 6
Yamao, Y., Ota, M., & Kanasaki, K. (2025) · Diabetology International · doi:10.1007/s13340-025-00839-5 · Cited by 7
“In FINEARTS-HF (mean eGFR 61.9 ml/min/1.73 m 2 ), the incidence of hyper-kalemia (>6.0 mmol/L) and serum creatinine ≥3.0 mg/dL in the finerenone group were 2.0% and 3.0%, respectively, during a median 32-month follow-up [21].”
Influential
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.